we refer to this as the reference population for the remainder of the manuscript
June 2025 On June 6, 2025, the European Medicines Agencys (EMA) safety committee concluded that Novo Nordisks semaglutide-containing drugsincluding the popular weight-loss drug Wegovy and diabetes treatments Ozempic and Rybelsusmay cause rare but serious cases of non-arteritic anterior ischemic optic neuropathy (NAION), a sudden and painless vision loss in one eye due to optic nerve damage
Schedule rest If rest isnt planned, it rarely happens
Decisions about starting, continuing, switching, or stopping any medication, including any GLP-1 receptor agonist, should be made in consultation with a licensed healthcare provider who knows your individual history, comorbidities, medications, and clinical context